Rivaroxaban

Rivaroxaban
Clinical data
Trade names	Xarelto, others
Other names	BAY 59-7939
AHFS/Drugs.com	Monograph
MedlinePlus	a611049
License data	US DailyMed: Rivaroxaban;
Pregnancy; category	AU: C;
Routes of; administration	By mouth
ATC code	B01AF01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: WARNINGRx-only; EU: Rx-only;
Pharmacokinetic data
Bioavailability	80–100%; Cmax = 2–4 hours (10 mg oral)
Metabolism	CYP3A4, CYP2J2 and CYP-independent mechanisms
Elimination half-life	5–9 hours in healthy subjects aged 20 to 45
Excretion	2/3 metabolized in liver and 1/3 eliminated unchanged
Identifiers
	IUPAC name (S)-5-chloro-N-{[2-oxo-3-[4-(3-oxomorpholin-4-yl); phenyl]oxazolidin-5-yl]methyl} thiophene-2-carboxamide;
CAS Number	366789-02-8 ;
PubChem CID	6433119;
IUPHAR/BPS	6388;
DrugBank	DB06228 ;
ChemSpider	8051086 ;
UNII	9NDF7JZ4M3;
KEGG	D07086 ;
ChEBI	CHEBI:68579;
ChEMBL	ChEMBL198362 ;
PDB ligand	RIV (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID3057723 ;
ECHA InfoCard	100.210.589
Chemical and physical data
Formula	C19H18ClN3O5S
Molar mass	435.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C1COCCN1c2ccc(cc2)N3C[C@@H](OC3=O)CNC(=O)c4ccc(s4)Cl;
	InChI InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1 ; Key:KGFYHTZWPPHNLQ-AWEZNQCLSA-N ;
	(what is this?) (verify)

Rivaroxaban, sold under the brand name Xarelto among others, is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. Specifically it is used to treat deep vein thrombosis and pulmonary emboli and prevent blood clots in atrial fibrillation and following hip or knee surgery. It is taken by mouth.

Common side effects include bleeding. Other serious side effects may include spinal hematoma and anaphylaxis. It is unclear if use in pregnancy and breastfeeding is safe. Compared to warfarin it has fewer interactions with other medications. It works by blocking the activity of the clotting protein factor Xa.

Rivaroxaban was patented in 2007 and approved for medical use in the United States in 2011. In the United States, it will not be available as a generic medication until 2024. It is on the World Health Organization's List of Essential Medicines. In 2021, it was the 86th most commonly prescribed medication in the United States, with more than 8 million prescriptions.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.